### CONTENTS

#### APRIL 2012 • VOLUME 2 • NUMBER 4

<table>
<thead>
<tr>
<th>IN THIS ISSUE</th>
<th>Highlighted research articles........................................ vi</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEWS IN BRIEF</td>
<td>Important news stories affecting the community.................... 291</td>
</tr>
<tr>
<td>NEWS IN DEPTH</td>
<td>Q&amp;A: Antoni Ribas on Immunotherapy Progress…….293</td>
</tr>
<tr>
<td></td>
<td>Speeding Discoveries with Neoadjuvant Studies ............ 294</td>
</tr>
<tr>
<td></td>
<td>The Science of Biosimilars…… 295</td>
</tr>
<tr>
<td>RESEARCH WATCH</td>
<td>Selected highlights of recent articles of exceptional significance from the cancer literature……………… 296</td>
</tr>
<tr>
<td>ONLINE</td>
<td>For more News and Research Watch, visit Cancer Discovery online at <a href="http://CDnews.aacrjournals.org">http://CDnews.aacrjournals.org</a>.</td>
</tr>
</tbody>
</table>

### VIEWS

**In The Spotlight**

- **A Spotlight from Prostate Cancer** .................. 301
  H.R. Herschman and J. Czernin
  *Commentary on Ulmert et al., p. 320*

- **Cancer Cell Metabolism: There Is No ROS for the Weary** .................. 304
  C.V. Dang
  *Commentary on Ros et al., p. 328*

### RESEARCH ARTICLES

- **The Role of the PGE2–Aromatase Pathway in Obesity-Associated Breast Inflammation** ............ 308
  D. Wang and R.N. DuBois
  *Commentary on Subbaramaiah et al., p. 356*

- **Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer** … 311
  S. ChandraLapapty

- **Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen** ...... 320
  *Précis: A PSA-targeted radiotracer specifically localizes to prostate tumors and bone metastases and quantifies responses to antiandrogen therapy.*

- **Functional Metabolic Screen Identifies 6-Phosphofructo-2-Kinase/ Fructose-2,6-Biphosphatase 4 as an Important Regulator of Prostate Cancer Cell Survival** ................. 328
  S. Ros, C.R. Santos, S. Maco, F. Baenke, G. Kelly, M. Howell, N. Zamboni, and A. Schulze
  *Précis: PFKFB4 regulates the balance between glycolysis and the pentose phosphate pathway to maintain redox homeostasis in prostate cancer cells.*
Metformin Accelerates the Growth of BrafV600E-Driven Melanoma by Upregulating VEGF-A 344
M.J. Martin, R. Hayward, A. Viros, and R. Marais

Précis: Metformin promotes BRAF-mutant melanoma growth via VEGF-A induction, but synergizes with VEGF inhibitors to suppress tumor growth.

Increased Levels of COX-2 and Prostaglandin E₂ Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women 356

Précis: Obesity-related breast inflammation increases aromatase activity and may therefore underlie an increased risk of hormone receptor-positive breast cancer.

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents 366

Précis: Increased allelic imbalance extending to the telomeres predicts response to platinum-based chemotherapy and may identify patients with defective DNA repair.

Correction
Correction: Genomic Complexity and AKT Dependence in Serous Ovarian Cancer 376

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

• The 24-hour, $1,000 Genome
• Delivering Quantum Dot Probes into the Cytosol
• DNA Nanorobot Signals Cancer Cells to Die
• Reporter Works with Multiple Imaging Types

ON THE COVER

Ulmert and colleagues developed ⁸⁹Zr–5A10, a radiolabeled monoclonal antibody that targets tumor-associated “free” prostate-specific antigen (PSA). The ⁸⁹Zr–5A10 radiotracer selectively and noninvasively detected and visualized prostate cancer xenografts and bone lesions, and could quantitatively measure changes in PSA production in response to antiandrogen therapy. These findings have implications for the clinical assessment of advanced prostate cancer and the evaluation of experimental therapies. For details, please see the article by Ulmert and colleagues on page 320.